Mineralys Therapeutics Completes $192M IPO
Summary
Mineralys Therapeutics, a US-based clinical-stage biopharmaceutical company, completed last Friday a $192m initial public offering (IPO) on the Nasdaq Global Select Market at $16.00 per share. Mineralys is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company has completed a Phase 2 study in uncontrolled and resistant hypertension and has announced positive results in November 2022. The IPO financing will support the company to advance its pivotal program in uncontrolled hypertension in the United States. Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company committed to developing a best-in-class, novel therapy for the treatment of hypertension, today announced the completion of an oversubscribed and up-sized $118 million Series B financing.